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Introduction
============

Severe hypertriglyceridemia (HTG) is a disorder characterized by elevated plasma triglyceride levels of \> 885 mg/dL (10.0 mmol/L)^[@bib1])^ or \> 1000 mg/dL (11.2 mmol/L)^[@bib2])^ and could lead to chylomicronemia syndrome. The clinical features of HTG include recurrent episodes of pancreatitis, abdominal pain with nausea and vomiting, hepatosplenomegaly, lipemia retinalis, and eruptive xanthomata^[@bib3]--[@bib5])^. It is also one of the most critical risk factors of atherosclerosis that can result in cerebrovascular^[@bib6])^ and cardiovascular diseases^[@bib7],\ [@bib8])^. Severe HTG is mainly divided into primary and secondary types. The common causes of secondary HTG are renal failure, nephrotic syndrome, diabetes mellitus, hypothyroidism, excessive alcohol or drug use, and some rare endocrine and metabolic disorders^[@bib9],\ [@bib10])^. Primary or genetic HTG with a monogenic etiology is less common and is characterized by the accumulation of TG-rich lipoproteins (chylomicrons, very low--density lipoprotein, and remnant lipoproteins) in the plasma^[@bib11]--[@bib13])^. These patients are usually carriers of homozygous or compound heterozygous loss-of-function mutations of genes for HTG, including *LPL, APOC2, APOA5, GPIHBP1, LMF1*, and *GPD1*.

LPL, a principal enzyme in plasma lipid metabolism, is synthesized in the endoplasmic reticulum (ER) of parenchymal cells in muscle and adipose tissue^[@bib14],\ [@bib15])^. It is the rate-limiting enzyme in tissues that hydrolyzes triglycerides in chylomicrons and very low--density lipoprotein (VLDL) and thereby makes fatty acids available for tissue metabolism^[@bib15])^. Meanwhile, macrophage foam cell formation is associated with triglyceride- rich lipoprotein (TGRL)-LPL-VLDL receptor pathway, which is a critical step in the initial stages of atherosclerotic process^[@bib16])^. As a result, the activity of LPL is a key determinant of tissue lipid partitioning and plasma TG clearance. LPL deficiency results in elevated plasma TGs^[@bib17])^. In adipocytes, lipase maturation is the conversion of the newly synthesized LPL into a catalytically active enzyme, which involves glycosylation, glycan processing, folding, and the assembly of homodimers^[@bib18])^. *LMF1* encodes a transmembrane protein chaperone localized to the ER membrane that is involved in the maturation of LPL and hepatic lipase (HL)^[@bib19],\ [@bib20])^. Patients with deleterious mutation in *LMF1* also show combined lipase deficiency (cld) with concomitant HTG and associated disorders^[@bib17])^.

According to the Human Gene Mutation Database, there are only 14 mutations that have been identified in previous mutation screenings of *LMF1* in patients with familial or sporadic HTG. In the present study, a compound heterozygous mutation (c.257C \> T/p.P86L and c.1184C \> T/p.T395I) in exons 2 and 8 of *LMF1* was identified and co-segregated with the affected patient in this family. Both mutations were first reported worldwide. Bioinformatics analysis predicted that both mutations were deleterious. Neither of them has been presented in the single nucleotide polymorphism (dbSNP) databases (<https://www.ncbi.nlm.nih.gov/projects/SNP/>) and Exome Variant Server databases (<http://evs.gs.washington.edu/EVS/>).

Materials and Methods
=====================

Patients
--------

In this study, a family of seven members from Jiangsu province across three generations, which was admitted to the Affiliated Hospital of Yangzhou University, 2017 (Yangzhou, China), was included (**[Fig. 1A](#F1){ref-type="fig"}**, **[Table 1](#T1){ref-type="table"}**). The proband was diagnosed with severe HTG with a plasma triglyceride level of 38.70 mmol/L. No severe HTG was present in the other family members. The present study was approved by the Ethics Committee of Yangzhou University (Yangzhou, China). All subjects provided consent prior to the commencement of the study.

![Pedigree and genetic analysis of the family with HTG\
(A) Pedigree of the family. Red and blue circles/squares are affected, white circles/squares are unaffected. Arrow indicates the proband. (B) Sanger DNA sequencing chromatogram demonstrates the heterozygosity for the mutations (c.257C \> T and c.1184C \> T) of *LMF1*. (C) Conservation analysis of *LMF1*. P86 and T395 sites are highlighted in red. This locus was found to be highly conserved at the protein level across different species.](jat-26-136-g001){#F1}

###### Summary of the family with severe HTG investigated

  Family member   TG (mmol/L)   Age (years)   *LMF1* mutations   Program prediction                                  
  --------------- ------------- ------------- ------------------ -------------------- ------------------- ---------- -----------------
  Ⅱ1 (proband)    38.7          51            257C \> T          P86L                 Probably Damaging   Damaging   Disease Causing
                                                                                      (0.998)             (0.003)    (0.999)
                                              1184C \> T         T395I                Possibly Damaging   Damaging   Disease Causing
                                                                                      (0.591)             (0.013)    (0.642)
  Ⅱ               N/A           70            N/A                N/A                  N/A                 N/A        N/A
  Ⅰ2              3.22          69            1184C \> T         T395I                Possibly Damaging   Damaging   Disease Causing
                                                                                      (0.591)             (0.013)    (0.642)
  Ⅱ2              1.52          50            Normal             Normal               N/A                 N/A        N/A
  Ⅱ3              1.44          47            Normal             Normal               N/A                 N/A        N/A
  Ⅱ4              2.99          45            1184C \> T         T395I                Possibly Damaging   Damaging   Disease Causing
                                                                                      (0.591)             (0.013)    (0.642)
  Ⅲ1              3.07          22            257C \> T          P86L                 Probably Damaging   Damaging   Disease Causing
                                                                                      (0.998)             (0.003)    (0.999)
  Ⅲ2              1.52          20            Normal             Normal               N/A                 N/A        N/A

HTG, hypertriglyceridemia; TG, triglyceride; *LMF1*, lipase maturation factor 1; N/A, not available.

DNA Extraction
--------------

Genomic DNA was extracted from the peripheral blood of the proband and other family members by using a DNeasy Blood and Tissue kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s protocol, on the QIAcube automated DNA extraction robot (Qiagen, Inc.).

Mutation Sequencing
-------------------

Several genes were amplified by polymerase chain reaction (PCR), including *LMF1* (Refseq: NM_022773), *LPL* (Refseq: NM_000237), *APOC2* (Refseq: NM_001646), *APOA5* (Refseq: NM_052968), *GPD1* (Refseq: NM_005276), and *GPIHBP1* (Refseq: NM_178172). PCR was performed using 25-µL reaction volumes, containing 0.3-mM dNTPs, 1X PCR buffer (10-mM Tris-HCl, pH 9.0; 50-mM KCl; 0.1% Triton X-100; and 0.01% w/v gelatin), 2.0-mM MgCl2, 0.5 µM of each primer, 1.5 U of Taq polymerase (Thermo Fisher Scientific, Inc., Waltham, MA, USA), and 50 ng of genomic DNA. Thermocycling conditions were as follows: Initial denaturation at 95°C for 5 min, followed by 35 cycles of amplification consisting of denaturation at 95°C for 30 sec, annealing at 55°C--61°C for 30 sec, and extension at 72°C for 1 min. A final extension step was performed at 72°C for 7 min. The sequences of the PCR products were obtained using the ABI 3100 genetic analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primers are supplied in **[Supplementary Table 1](#T2){ref-type="table"}**.

###### Primers sequences used for mutation sequencing of LMF1, APOA5, APOC2, GPIHBP1, LPL and GPD1 genes

  Gene        Forward 5′ → 3′          Reverse 5′ → 3′
  ----------- ------------------------ -----------------------------
  LMF1-1      AACTGCGAAGGAGGCAGGC      GCGGAGGAGTCTCGAGGGAG
  LMF1-2      TGCCTCGCCCCGCATTCT       AGCTCCGACCGCCCCATT
  LMF1-3      GGTTGAAACAAGCCAAAGTGT    AGATCACAAGCGCCCATC
  LMF1-4      CTTGCGTGTCGATGTTGA       GGTTAGAAGAGCCACCGTTA
  LMF1-5      CCCTTCTCAAATTCTGCCTTCC   TGATGCGACAGCTCACCAG
  LMF1-6      CTCTTAGCGTGGCAGGTGG      CAAACGAAGGCTGGGGAG
  LMF1-7      GGCACAGCTGGGTTTCA        TGAGCCACCTACCGAATCT
  LMF1-8      GCGTGCCAGGAACAAGGT       TGTCCAGGCCCGGTAGTG
  LMF1-9      GGGCCACAGTTCCCAAA        CGTTCTAGAAACCTGCCATCTAT
  LMF1-10     GAACCCACCTCCAGGAAAG      TGATGCCAAGGCTGATGT
  LMF1-11     TTGCTGCGCTGTTCACT        GCTGGGTCTTCGCCTTTATT
  APOA5-1     TGTCCCTTCGTCTCCTTCTT     CTGTGGAGAGGGACTAGGTAAT
  APOA5-2     CTGATTACCTAGTCCCTCTCCA   AACAGCTACGGAGTTGTCAAG
  APOA5-3-1   GGGACAAAGGAGATGATGGA     TCGGCGTATGGGTGGAAG
  APOA5-3-2   CTGAAGCCCTACACGATGGA     GCGGAAAGCCTGAAGTCG
  APOA5-3-3   GGCACTGGGACTGAGGAAG      GACAAGGAGCTGGGAATGG
  APOC2-1     TGGGAAACTTGACTGGGACA     GGCTGGGAAGATGCTTGG
  APOC2-2     CCTGGTATTGGGATTTGGT      AACTTCTGGGTCCTGGATG
  APOC2-3     CCCCTCCTCCCTCTAACCA      GTGCCATCCATGAGAAGCAA
  GPIHBP1-1   ATGCCCTTCATCCCACTTACC    GCTTCCATCCATGCTGCTCT
  GPIHBP1-2   GTAGGGTGTTCAGGGTAGGG     CAGAATGCTCCAGGCAGAT
  GPIHBP1-3   CTCACCAGGCTAGGCTTTGG     TGGAGTGGGTGGTCAGGAGG
  GPIHBP1-4   CGCCCATCCTCAGCACTT       CGCCCAAGACACTCCAAATC
  LPL-1       GGAAAGCTGCCCACTTCTA      TTCCTTCTTCTCATCCTCAGTTC
  LPL-2       TGGTTGCCTGTGAACCTAAA     CCTGAGCCAGAACTGTCTTTAT
  LPL-3       GACAAGTGGTAGGTGGGTATTT   CCACGCTGATTCTGAAGATTTG
  LPL-4       GGCAGAACTGTAAGCACCTT     CCTAATAAAGAGCCCTACAATGAGATA
  LPL-5       GCCAGTGCATTCAAATGATGAG   TGGGTCAATAAGGGTTAAGGATAAG
  LPL-6       ATGCCAAATGAAACACTC       TTAGAAGCCTCAGACAAA
  LPL-7       CTTCCGGTTTGAGTGCTAGT     TGCTCAGACCAAGGGTTATG
  LPL-8       TGAGTTCTTTGTTGGACA       CTGAAATACAGCCCCTAG
  LPL-9       TCCTGACAGAACTGTACCTTTG   GGATGCCCAGTCAGCTTTA
  GPD1-1      TCCTTTCCCTGGCTCTGC       CCTCCTACCCACCTCTGTCTT
  GPD1-2      GGGACTATTTGTCATGGGAGT    GAGGCACCTGTTGAGTAAGG
  GPD1-3      CCAAACAAGCCTTCCTGC       CTCCTTGCTTCACCCACC
  GPD1-4      TGGCCTCCTCACAGCAAA       TCCCAGCCTCCTTCACCT
  GPD1-5      TAAGCCCAGGAGTTTGAG       CACGGTCTGATGATGAATAA
  GPD1-6      GTCACGGCTGATGAAATGA      CAAGCACCTCTACCTGGAT
  GPD1-7      TCTGTAGGCATCCAGGTAG      AGATTTGTGGCAGGTTTAG
  GPD1-8      GGAGGGTTAGGCAGTGAG       TTTCTGGCAAATGTGGTG

Bioinformatics Analysis and Mutation Prediction
-----------------------------------------------

Multiple *LMF1* protein sequences were aligned in several species (version 3.6; <http://www.ncbi.nlm.nih.gov>). Polymorphism Phenotyping-2^[@bib21])^, Sorting Intolerant From Tolerant^[@bib22])^, and MutationTaster^[@bib23])^ were used to predict the effects of these sequence variants on the function of LMF1 protein.

LPL and HL Assays
-----------------

We measured the pre-heparin and post-heparin LPL and HL activity. Blood samples were collected from the proband and his brother (Ⅱ-3) after an overnight fast. Their blood was collected again 15 min after an intravenous bolus injection of heparin (100 IU/kg). His brother was set as a normal control for triglyceride. LPL and HL activity assays of other family members were not performed because they refused to receive heparin. LPL and HL activities were measured as previously described^[@bib24])^. LPL and HL activities were detected by LPL Activity Assay Kit (Sigma, Roar Biomedical Inc.). Each assay was performed in three independent tests. The data were analyzed by unpaired two-tailed tests using Graph Pad Prism V.5 software (V.5.0).

Result
======

Clinical Case
-------------

We reported a case of a 51-year-old man who was hospitalized for mild left-sided hemiplegia (**[Fig. 1A](#F1){ref-type="fig"}**, **[Table 1](#T1){ref-type="table"}**). Magnetic resonance imaging confirmed the diagnosis of lacunar infarction. Lipid profile assessment revealed the presence of HTG (TG, 38.70 mmol/L). His body mass index was 24.7 kg/m^2^. He had a history of pancreatitis, but did not have a history of diabetes, hypertension, smoking, or alcohol abuse. However, he had a family history of cardiovascular disease: His father had died of coronary heart disease at the age of 70 years. Secondary causes of severe HTG were ruled out. An impaired glucose tolerance was indicated by an HbA1c of 5.6%. Doppler ultrasound showed that he had atherosclerotic changes with plaques in the right internal carotid artery. Diffusion- weighted imaging showed lacunar infarction of right basal ganglia, while magnetic resonance angiography showed multiple intracranial vascular stenosis. Another three family members showed the HTG phenotype, but the levels of TG were not very high (**[Table 1](#T1){ref-type="table"}**).

Molecular Genetic Analysis
--------------------------

The possibility of HTG induction by known genes was investigated. Two missense mutations (c.257C \> T/p.P86L and c.1184C \> T/p.T395I) in *LMF1* were identified by using Sanger sequencing, and they were co-segregated with the affected members (**[Fig. 1B](#F1){ref-type="fig"}**). The allelic segregation analysis revealed that the c.1184C \> T/p.T395I mutation was carried by the mother, whereas the c.257C \> T/p.P86L mutation was speculated to be inherited from the father. These two novel mutations (c.257C \> T/p.P86L and c.1184C \> T/p.T395I) caused a substitution of proline by leucine and a substitution of threonine by isoleucine in *LMF1*. The maximum frequency values (MAF) of both mutations in Exome Aggregation Consortium and TGP (1000 genomes project) database were less than 0.001. Both mutations were not found in our 200 control cohorts, as well as in dbSNP and Exome Variant Server database . The amino acid sequences of *LMF1* were found to be aligned in humans, rhesus monkeys, mice, dogs, chicken, and zebrafishes, which revealed that the affected amino acids were evolutionarily conserved (**[Fig. 1C](#F1){ref-type="fig"}**). The two variants were probably damaging (c.257C \> T/p. P86L) and possibly damaging (c.1184C \> T/p.T395I) in Polyphen-2, were both damaging in SIFT, and were disease causing in MutationTaste. The uniformity among the detrimental effects of the variants as predicted by all these bioinformatics programs suggested that these mutations are important in the function of LMF1.

LPL and HL Activities
---------------------

We measured the post-heparin LPL and HL activities of the proband and a normal plasma triglyceride family member (II3) as a control. The levels of the plasma post-heparin LPL and HL activities in the proband (57 and 177 mU/mL) were reduced to 24% and 75%, respectively, compared with those assayed in the normal plasma triglyceride control (**[Fig. 2](#F2){ref-type="fig"}**).

![Pre-heparin and post-heparin LPL and HL activity were assayed in the proband and a normal plasma triglyceride control\
The levels of the plasma post-heparin LPL and HL activity in the proband (57 and 177 mU/mL) were reduced to 24% and 75%, respectively, compared with those assayed in the normal plasma triglyceride control.](jat-26-136-g002){#F2}

Discussion
==========

In this study, we report a severe HTG patient with mild stroke associated with a compound heterozygous mutation (c.257C \> T/p.P86L and c.1184C \> T/p.T395I) in exons 2 and 8 of *LMF1*. Our study is consistent with the previous reports that only homozygous and compound heterozygous mutations in *LMF1* are responsible for HTG^[@bib17],\ [@bib25])^. At the same time, we found that the LPL and HL activities were lower in the proband than in the healthy subject. At present, 14 point mutations of *LMF1* have been reported in HTG patients (**[Fig. 3A](#F3){ref-type="fig"}**). The outcome of the molecular genetic investigations performed in the present study was consistent with previous studies^[@bib17],\ [@bib25])^, which indicated that mutations in *LMF1* could cause HTG due to the decreasing activities of LPL and HL.

![Summary of mutation Structure analysis of *LMF1*\
(A) Summary of missense, nonsense, or splicing mutations in *LMF1* associated with hypertriglyceridemia. Mutations identified in the present study are indicated in red. (B) Schematic of *LMF1*\'s topology. Mutation (c.257C \> T/p.P86L) located in loop-A and the other mutation (c.1184C \> T/p.T395I) located in the C-terminus domain are indicated in red.](jat-26-136-g003){#F3}

Combined lipase deficiency (cld) is a recessive mutation located on mouse chromosome 17 that exhibits severely deficient LPL activity^[@bib26])^. Homozygous cld mutant mice develop extreme HTG as a result of severe deficiency in plasma LPL and HL activities and die within 48 hours or a few days after birth^[@bib26],\ [@bib27])^. The precise genetic location of *LMF1*, which encodes an ER-resident, transmembrane protein containing cld, has been identified^[@bib17])^. *LMF1* plays a critical role in the post-translational maturation of LPL and HL. Deleterious mutations in *LMF1* gene result in severe HTG^[@bib17],\ [@bib25])^. Our study also demonstrated that lipase activities, especially the LPL activity, in the proband decreased significantly.

Previous studies revealed that LMF1 is a multipass transmembrane protein of the ER that has five transmembrane domains, with its three soluble domains and C-terminus in the ER lumen and N-terminus in the cytosol. The loops (labeled A--D) connect all these domains (**[Fig. 3B](#F3){ref-type="fig"}**). This subcellular structure is consistent with the post-translational effect of *LMF1* for the maturation of lipases, as these enzymes attain catalytic activity within the ER^[@bib28],\ [@bib29])^. It is also demonstrated that the loop C and the C-terminus of *LMF1* are important for dimeric lipase maturation^[@bib30])^. Indeed, two nonsense mutations (Y439X and W464X) in the C-terminal ER domain of *LMF1* resulted in truncated variants^[@bib17],\ [@bib25])^. In both cases, severe HTG were associated with deficiency for lipase maturation. In the present study, these two mutations are both located in the ER lumen. The novel mutation (c.257C \> T/p.P86L) located in loop-A domain resulted in the substitution of proline by leucine. The loop-A domain of *LMF1* is a part of lipase-binding domain and plays a crucial role in activating lipase activity^[@bib19],\ [@bib30],\ [@bib31])^. Another novel mutation (c.1184C \> T/p.T395I) located in the highly conserved C-terminus domain, which is also part of the lipase maturation domain, contributes to the maturation of lipase. Consequently, they may both affect the function of *LMF1*, further down-regulate the activities of LPL and HL and lead to HTG.

Previous studies have confirmed that nonsense mutation of *LMF1* affects the activity of lipoprotein lipase and can cause HTG^[@bib17],\ [@bib25])^. Patients carrying p.Y439X mutation showed severe HTG, recurrent episodes of pancreatitis, and diabetes mellitus. However, another patient harboring p.W464X mutation only presented HTG^[@bib17])^. The differences indicated that mutations in *LMF1* may show high genetic heterogeneity and complexity in a diverse genetic architecture^[@bib32],\ [@bib33])^.

In-depth diagnostic strategies of HTG are not routinely used in clinical works due to the costs of genetic analysis and the low prevalence of severe HTG. In this study, we have shown that a molecular diagnosis is feasible and effective in carefully selected patients with severe HTG. Fortunately, a highly accurate customized generation sequencing (NGS) panel for targeted gene sequencing of 18 genes involved in HTG has been recently developed, which offers the possibility to perform massively parallel sequencing that can produce enormous amounts of data and allow analysis of genes in a short period of time, easily and relatively economically^[@bib34])^. Differential therapeutic strategies may be developed by unraveling the underlying molecular "defect." In the last decades, different types of vectors have been used in clinical trials for treating several monogenetic disorders. A recent study showed that *LPL* gene therapy had been used successfully in patients with genetic LPL deficiency, and the follow-up study is ongoing to definitively confirm the long-term benefit and safety of this approach^[@bib35])^. However, there are currently no clear treatment options for *LMF1* deficiency. Currently, only one research has reported that fibrate drug combination therapy + insulin may decrease the level of TG in patients with *LMF1* mutation^[@bib25])^. Fibrates are widely used clinically to treat HTG. They activate peroxisome proliferator-activated receptors (PPARs), especially PPAR*α*. PPARs can modulate fat metabolism and adipose tissue differentiation. They can further upregulate the transcription of multiple genes that facilitate lipid metabolism, such as apolipoprotein (apo) A-5 and LPL, and downregulate the transcription of apoC-3. However, fibrates have less selectivity for PPAR*α* and are associated with a high risk of side effects^[@bib36])^. Recently, K-877 (Pemafibrate) has been shown to have higher PPAR*α* agonistic activity and selectivity than fibrates^[@bib37])^. In a recent study, Sairyo *et al.* used K-877 to treat a mouse model with diet-induced HTG. The result revealed that K-877 and fenofibrate could both increase the activity of LPL and decrease the level of serum TG. Moreover, K-877 may attenuate postprandial HTG more effectively than fenofibrate by suppressing the postprandial increase of chylomicrons and the accumulation of chylomicron remnants^[@bib38])^. In our subsequent work, we plan to treat our patient with K-877. We hope this measure can decrease the TG level of the proband and provide more acute therapy examples for clinic.

In conclusion, the present study identified an *LMF1* compound heterozygous mutation (c.257C \> T/p.P86L and c.1184C \> T/p.T395I) in a patient with severe HTG. To the best of our knowledge, this is the first report of these two mutations worldwide. The results of the present study offer further support for the significant involvement of *LMF1* in severe HTG. The results also expand on the spectrum of *LMF1* mutations and contribute to the genetic diagnosis and counseling of families with severe HTG.
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